ABT-263
Showing 1 - 25 of 402
Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level
Not yet recruiting
- Relapsed Adult AML
- Refractory AML
- Navitoclax Dose Level -1
- +10 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Aug 17, 2023
Chronic Lymphocytic Leukemia Trial in Worldwide (ABT-263)
Completed
- Chronic Lymphocytic Leukemia
- ABT-263
-
La Jolla, California
- +9 more
Jul 8, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine, Navitoclax, Venetoclax)
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Decitabine
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 15, 2022
Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Boston
Active, not recruiting
- Metastatic Malignant Solid Neoplasm
- +2 more
- Biopsy
- +6 more
-
Boston, Massachusetts
- +1 more
Nov 8, 2022
Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)
Not yet recruiting
- Mantle Cell Lymphoma Refractory
- Ibrutinib
- +3 more
- (no location specified)
May 16, 2023
Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma Trial in Dallas (Venetoclax, Navitoclax)
Available
- Relapsed Childhood ALL
- Relapsed Childhood Lymphoblastic Lymphoma
-
Dallas, TexasUniversity of Texas Southwestern Medical Center
Feb 28, 2022
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome Trial in Philadelphia
Recruiting
- Myelodysplastic Syndrome
- +2 more
- Navitoclax
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Feb 2, 2023
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia Trial in Memphis (drug, biological, radiation)
Not yet recruiting
- Refractory Acute Lymphoblastic Leukemia
- Relapsed Acute Lymphoblastic Leukemia
- Venetoclax
- +16 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Aug 23, 2022
Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma Trial in Canada, United States (ABT-263)
Completed
- Chronic Lymphoid Leukemia
- +5 more
- ABT-263
-
Los Angeles, California
- +11 more
Jul 28, 2021
High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer Trial (Olaparib tablet, Navitoclax)
Recruiting
- High Grade Serous Carcinoma
- +2 more
- Olaparib tablet
- Navitoclax
-
Toronto, Ontario, Canada
- +2 more
Nov 28, 2022
Metastatic Malignant Solid Tumor, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Tumor Trial in United States
Terminated
- Metastatic Malignant Solid Neoplasm
- +8 more
- Navitoclax
- Vistusertib
-
Los Angeles, California
- +13 more
Oct 7, 2022
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung
Active, not recruiting
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma
- +5 more
-
Sacramento, California
- +17 more
Aug 2, 2022
Myelofibrosis (MF) Trial in Korea, Republic of, South Africa, United States (Mivebresib, Navitoclax, Ruxolitinib)
Active, not recruiting
- Myelofibrosis (MF)
- Mivebresib
- +2 more
-
Stony Brook, New York
- +6 more
Mar 23, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Tumor Trial in
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Dabrafenib
- +4 more
-
Phoenix, Arizona
- +48 more
Jan 3, 2023
Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Trial in Australia, United States (Navitoclax, Chemotherapy,
Completed
- Acute Lymphoblastic Leukemia (ALL)
- Lymphoblastic Lymphoma
- Navitoclax
- +2 more
-
Duarte, California
- +14 more
Oct 7, 2021
Platinum-resistant or Refractory Ovarian Cancer Trial in France (ABT-263)
Completed
- Platinum-resistant or Refractory Ovarian Cancer
- ABT-263
-
Besançon, France
- +15 more
Mar 15, 2019
Advanced Systemic Mastocytosis Trial (BLU-263, Azacitidine)
Not yet recruiting
- Advanced Systemic Mastocytosis
- (no location specified)
Nov 2, 2022
Chronic Hepatitis C, Hepatitis C Virus Trial (ABT-493, ABT-530, ribavirin (RBV))
HIV/AIDS Trial in Beijing (Albuvirtide, 3BNC117)
Not yet recruiting
- HIV/AIDS
-
Beijing, ChinaPeking Union Medical College Hospital
Mar 24, 2021
Rheumatoid Arthritis Trial in Matsumoto (Drug: "Salirumab", Drug: "Tocilizmab", Drug: "Abatacept")
Recruiting
- Rheumatoid Arthritis
- Drug: "Salirumab"
- +2 more
-
Matsumoto, Nagano, JapanYukio Nakamura
Sep 20, 2021
Chronic Hepatitis C Virus (HCV) Infection Genotype 1 Trial in United States (ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV))
Completed
- Chronic Hepatitis C Virus (HCV) Infection Genotype 1
- ABT-450/r/ABT-267
- +2 more
-
Phoenix, Arizona
- +47 more
Jun 27, 2022